近10年中医治疗原发性肝癌用药规律研究
2016-12-03刘鸣昊李柯柯张丽慧贾涵婷赵文霞
刘鸣昊 李柯柯 张丽慧 贾涵婷 赵文霞
摘要:目的 分析近10年中医治疗原发性肝癌的用药规律,为临床用药提供参考。方法 计算机检索中国知识资源总库(CNKI)、中文科技期刊数据库(VIP)、中国学术期刊数据库(万方数据)2005年1月-2015年9月中医治疗原发性肝癌临床研究相关文献,统计药物所属类别及使用频次。结果 经筛选,共纳入文献131篇,涉及中药复方131首、药物228味,药物总使用频次1416次。使用频次较高的药物类别依次为补虚药430次(30.37%)、利水渗湿药233次(16.45%)、活血化瘀药184次(12.99%)等。使用频次较高的药物依次为白术64次(4.52%)、茯苓62次(4.38%)、甘草52次(3.67%)、柴胡49次(3.46%)、白芍45次(3.18%)、黄芪44次(3.11%)、莪术43次(3.04%)、茵陈41次(2.90%)等。结论 本研究总结了近10年中医治疗原发性肝癌的用药类别及使用频次,可为临床治疗提供数据支持。
关键词:原发性肝癌;中医;用药规律
DOI:10.3969/j.issn.1005-5304.2016.09.011
中图分类号:R273.57;R2-05 文献标识码:A 文章编号:1005-5304(2016)09-0045-03
Study on Medication Rules of TCM Treatment for Primary Hepatic Carcinoma in Recent Ten Years LIU Ming-hao1, LI Ke-ke2, ZHANG Li-hui1, JIA Han-ting3, ZHAO Wen-xia1 (1. The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, China; 2. Henan University of Chinese Medicine, Zhengzhou 450000, China; 3. The Third Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, China)
Abstract: Objective To analyze medication rules of TCM treatment for primary hepatic carcinoma in recent ten years; To provide references for clinical medication. Methods Literature about primary hepatic carcinoma in CNKI, VIP and Wanfang database from January 2005 to September 2015 was searched by computers to carry out statistical analysis of medicine classification and frequency of usage. Results Through screening, 131 articles were included, covering 131 compound TCM prescriptions, 228 kinds of medicine, and 1416 times of frequency of usage. Medicines with relatively high frequency were tonifying deficiency medicine 430 times (30.37%), damp-clearing medicine 233 times (16.45%), medicine for invigorating blood circulation and eliminating stasis (12.99%). Medicines with relatively high frequency were Atractylodis Macrocephalae Rhizoma 64 times (4.52%), Poria 62 times (4.38%), Glycyrrhizae Radix et Rhizoma 52 times (3.67%), Bupleuri Radix 49 times (3.46%), Paeoniae Radix Alba 45 times (3.18%), Astragali Radix 44 times (3.22%), Curcumae Rhizoma 43 times (3.04%), and Artemisiae Scopariae Herba 41 times (2.90%). Conclusion This study summarizes the medicine classification and frequency of usage of TCM treatment for primary hepatic carcinoma in recent ten years, which can provide data support for clinical treatment.
Key words: primary hepatic carcinoma; TCM; medication rules
原发性肝癌是指原发于肝细胞或肝内胆管细胞的恶性肿瘤,为我国常见的多发性恶性癌症。由于其起病隐匿,发现时多已处于晚期,目前多采用肝动脉
基金项目:国家自然科学基金(81473651);河南中医学院 博士科研基金(BSJJ2014-19)
通讯作者:赵文霞,E-mail:zhao-wenxia@163.com
化疗栓塞(TACE)进行治疗,虽然疗效显著,但存在不良反应,对机体产生一些继发性的损伤,影响患者以后的生活质量。中医的整体观理念,通过辨证论治合理用药,起到扶正抑瘤抗癌的双重作用,对延长患者生存期、提高其生活质量有着重要的意义[1]。本研究通过分析近10年中医治疗原发性肝癌相关文献用药规律,为该病的临床用药提供借鉴。……
